Frontiers of Medicine最新文献

筛选
英文 中文
Innovation-driven trend shaping COVID-19 vaccine development in China 中国 COVID-19 疫苗研发的创新驱动趋势
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-16 DOI: 10.1007/s11684-023-1034-6
Yuntao Zhang, Yuxiu Zhao, Hongyang Liang, Ying Xu, Chuge Zhou, Yuzhu Yao, Hui Wang, Xiaoming Yang
{"title":"Innovation-driven trend shaping COVID-19 vaccine development in China","authors":"Yuntao Zhang, Yuxiu Zhao, Hongyang Liang, Ying Xu, Chuge Zhou, Yuzhu Yao, Hui Wang, Xiaoming Yang","doi":"10.1007/s11684-023-1034-6","DOIUrl":"https://doi.org/10.1007/s11684-023-1034-6","url":null,"abstract":"<p>Confronted with the Coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized. Likewise, new technologies may provide more potent or broader immunity and will contribute to fight against hypermutated SARS-CoV-2 variants. All in all, with the ultimate aim of delivering robust and durable protection that is resilient to emerging infectious disease, alongside the traditional routes, the discovery of innovative approach to developing effective vaccines based on virus properties remains our top priority.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":"197 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138692020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GID complex regulates the differentiation of neural stem cells by destabilizing TET2. GID 复合物通过破坏 TET2 的稳定性来调节神经干细胞的分化。
IF 3.9 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-14 DOI: 10.1007/s11684-023-1007-9
Meiling Xia, Rui Yan, Wenjuan Wang, Meng Zhang, Zhigang Miao, Bo Wan, Xingshun Xu
{"title":"GID complex regulates the differentiation of neural stem cells by destabilizing TET2.","authors":"Meiling Xia, Rui Yan, Wenjuan Wang, Meng Zhang, Zhigang Miao, Bo Wan, Xingshun Xu","doi":"10.1007/s11684-023-1007-9","DOIUrl":"10.1007/s11684-023-1007-9","url":null,"abstract":"<p><p>Brain development requires a delicate balance between self-renewal and differentiation in neural stem cells (NSC), which rely on the precise regulation of gene expression. Ten-eleven translocation 2 (TET2) modulates gene expression by the hydroxymethylation of 5-methylcytosine in DNA as an important epigenetic factor and participates in the neuronal differentiation. Yet, the regulation of TET2 in the process of neuronal differentiation remains unknown. Here, the protein level of TET2 was reduced by the ubiquitin-proteasome pathway during NSC differentiation, in contrast to mRNA level. We identified that TET2 physically interacts with the core subunits of the glucose-induced degradation-deficient (GID) ubiquitin ligase complex, an evolutionarily conserved ubiquitin ligase complex and is ubiquitinated by itself. The protein levels of GID complex subunits increased reciprocally with TET2 level upon NSC differentiation. The silencing of the core subunits of the GID complex, including WDR26 and ARMC8, attenuated the ubiquitination and degradation of TET2, increased the global 5-hydroxymethylcytosine levels, and promoted the differentiation of the NSC. TET2 level increased in the brain of the Wdr26<sup>+/-</sup> mice. Our results illustrated that the GID complex negatively regulates TET2 protein stability, further modulates NSC differentiation, and represents a novel regulatory mechanism involved in brain development.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1204-1218"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10234969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca2+ homeostasis in a murine model of HFpEF. 小檗碱通过调节 Drp1 介导的线粒体分裂和 Ca2+ 平衡,缓解小鼠高频心衰模型的心肌舒张功能障碍。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-01 DOI: 10.1007/s11684-023-0983-0
Miyesaier Abudureyimu, Mingjie Yang, Xiang Wang, Xuanming Luo, Junbo Ge, Hu Peng, Yingmei Zhang, Jun Ren
{"title":"Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca<sup>2+</sup> homeostasis in a murine model of HFpEF.","authors":"Miyesaier Abudureyimu, Mingjie Yang, Xiang Wang, Xuanming Luo, Junbo Ge, Hu Peng, Yingmei Zhang, Jun Ren","doi":"10.1007/s11684-023-0983-0","DOIUrl":"10.1007/s11684-023-0983-0","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) displays normal or near-normal left ventricular ejection fraction, diastolic dysfunction, cardiac hypertrophy, and poor exercise capacity. Berberine, an isoquinoline alkaloid, possesses cardiovascular benefits. Adult male mice were assigned to chow or high-fat diet with L-NAME (\"two-hit\" model) for 15 weeks. Diastolic function was assessed using echocardiography and noninvasive Doppler technique. Myocardial morphology, mitochondrial ultrastructure, and cardiomyocyte mechanical properties were evaluated. Proteomics analysis, autophagic flux, and intracellular Ca<sup>2+</sup> were also assessed in chow and HFpEF mice. The results show exercise intolerance and cardiac diastolic dysfunction in \"two-hit\"-induced HFpEF model, in which unfavorable geometric changes such as increased cell size, interstitial fibrosis, and mitochondrial swelling occurred in the myocardium. Diastolic dysfunction was indicated by the elevated E value, mitral E/A ratio, and E/e' ratio, decreased e' value and maximal velocity of re-lengthening (-dL/dt), and prolonged re-lengthening in HFpEF mice. The effects of these processes were alleviated by berberine. Moreover, berberine ameliorated autophagic flux, alleviated Drp1 mitochondrial localization, mitochondrial Ca<sup>2+</sup> overload and fragmentation, and promoted intracellular Ca<sup>2+</sup> reuptake into sarcoplasmic reticulum by regulating phospholamban and SERCA2a. Finally, berberine alleviated diastolic dysfunction in \"two-hit\" diet-induced HFpEF model possibly because of the promotion of autophagic flux, inhibition of mitochondrial fragmentation, and cytosolic Ca<sup>2+</sup> overload.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1219-1235"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke. 2019年冠状病毒病相关中风的流行病学、发病机制和管理。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2024-01-02 DOI: 10.1007/s11684-023-1041-7
Lu Liu, Chenxia Zhou, Huimin Jiang, Huimin Wei, Yifan Zhou, Chen Zhou, Xunming Ji
{"title":"Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.","authors":"Lu Liu, Chenxia Zhou, Huimin Jiang, Huimin Wei, Yifan Zhou, Chen Zhou, Xunming Ji","doi":"10.1007/s11684-023-1041-7","DOIUrl":"10.1007/s11684-023-1041-7","url":null,"abstract":"<p><p>The Coronavirus disease 2019 (COVID-19) epidemic has triggered a huge impact on healthcare, socioeconomics, and other aspects of the world over the past three years. An increasing number of studies have identified a complex relationship between COVID-19 and stroke, although active measures are being implemented to prevent disease transmission. Severe COVID-19 may be associated with an increased risk of stroke and increase the rates of disability and mortality, posing a serious challenge to acute stroke diagnosis, treatment, and care. This review aims to provide an update on the influence of COVID-19 itself or vaccines on stroke, including arterial stroke (ischemic stroke and hemorrhagic stroke) and venous stroke (cerebral venous thrombosis). Additionally, the neurovascular mechanisms involved in SARS-CoV-2 infection and the clinical characteristics of stroke in the COVID-19 setting are presented. Evidence on vaccinations, potential therapeutic approaches, and effective strategies for stroke management has been highlighted.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1047-1067"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lack of CFAP54 causes primary ciliary dyskinesia in a mouse model and human patients. 在小鼠模型和人类患者中,缺乏CFAP54会导致原发性纤毛运动障碍。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-19 DOI: 10.1007/s11684-023-0997-7
Xinyue Zhao, Haijun Ge, Wenshuai Xu, Chongsheng Cheng, Wangji Zhou, Yan Xu, Junping Fan, Yaping Liu, Xinlun Tian, Kai-Feng Xu, Xue Zhang
{"title":"Lack of CFAP54 causes primary ciliary dyskinesia in a mouse model and human patients.","authors":"Xinyue Zhao, Haijun Ge, Wenshuai Xu, Chongsheng Cheng, Wangji Zhou, Yan Xu, Junping Fan, Yaping Liu, Xinlun Tian, Kai-Feng Xu, Xue Zhang","doi":"10.1007/s11684-023-0997-7","DOIUrl":"10.1007/s11684-023-0997-7","url":null,"abstract":"<p><p>Primary ciliary dyskinesia (PCD) is a highly heterogeneous recessive inherited disorder. FAP54, the homolog of CFAP54 in Chlamydomonas reinhardtii, was previously demonstrated as the C1d projection of the central microtubule apparatus of flagella. A Cfap54 knockout mouse model was then reported to have PCD-relevant phenotypes. Through whole-exome sequencing, compound heterozygous variants c.2649_2657delinC (p. E883Dfs*47) and c.7312_7313insCGCAGGCTGAATTCTTGG (p. T2438delinsTQAEFLA) in a new suspected PCD-relevant gene, CFAP54, were identified in an individual with PCD. Two missense variants, c.4112A>C (p. E1371A) and c.6559C>T (p. P2187S), in CFAP54 were detected in another unrelated patient. In this study, a minigene assay was conducted on the frameshift mutation showing a reduction in mRNA expression. In addition, a CFAP54 in-frame variant knock-in mouse model was established, which recapitulated the typical symptoms of PCD, including hydrocephalus, infertility, and mucus accumulation in nasal sinuses. Correspondingly, two missense variants were deleterious, with a dramatic reduction in mRNA abundance from bronchial tissue and sperm. The identification of PCD-causing variants of CFAP54 in two unrelated patients with PCD for the first time provides strong supportive evidence that CFAP54 is a new PCD-causing gene. This study further helps expand the disease-associated gene spectrum and improve genetic testing for PCD diagnosis in the future.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1236-1249"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Passive antibody therapy in emerging infectious diseases. 新发传染病的被动抗体治疗。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-12-02 DOI: 10.1007/s11684-023-1021-y
Xiaoming Yang
{"title":"Passive antibody therapy in emerging infectious diseases.","authors":"Xiaoming Yang","doi":"10.1007/s11684-023-1021-y","DOIUrl":"10.1007/s11684-023-1021-y","url":null,"abstract":"<p><p>The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 years. Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonal antibodies (mAbs) applied in passive immunotherapy have yielded positive outcomes and played a crucial role in the early COVID-19 treatment. In this review, the development path, action mechanism, clinical research results, challenges, and safety profile associated with the use of COVID-19 convalescent plasma, hyperimmunoglobulin, and mAbs were summarized. In addition, the prospects of applying antibody therapy against VOCs was assessed, offering insights into the coping strategies for facing new infectious disease outbreaks.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1117-1134"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138470183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisiting China's response to coronavirus disease 2019. 重新审视 2019 年中国应对冠状病毒疾病的措施。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2024-02-01 DOI: 10.1007/s11684-024-1059-5
Guangbiao Zhou, Saijuan Chen, Zongjiu Zhang, Zhu Chen
{"title":"Revisiting China's response to coronavirus disease 2019.","authors":"Guangbiao Zhou, Saijuan Chen, Zongjiu Zhang, Zhu Chen","doi":"10.1007/s11684-024-1059-5","DOIUrl":"10.1007/s11684-024-1059-5","url":null,"abstract":"","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1011-1013"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicle-carried GTF2I from mesenchymal stem cells promotes the expression of tumor-suppressive FAT1 and inhibits stemness maintenance in thyroid carcinoma. 间充质干细胞携带的细胞外囊泡GTF2I可促进抑制肿瘤的FAT1的表达,并抑制甲状腺癌的干性维持。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-14 DOI: 10.1007/s11684-023-0999-5
Jie Shao, Wenjuan Wang, Baorui Tao, Zihao Cai, Haixia Li, Jinhong Chen
{"title":"Extracellular vesicle-carried GTF2I from mesenchymal stem cells promotes the expression of tumor-suppressive FAT1 and inhibits stemness maintenance in thyroid carcinoma.","authors":"Jie Shao, Wenjuan Wang, Baorui Tao, Zihao Cai, Haixia Li, Jinhong Chen","doi":"10.1007/s11684-023-0999-5","DOIUrl":"10.1007/s11684-023-0999-5","url":null,"abstract":"<p><p>Through bioinformatics predictions, we identified that GTF2I and FAT1 were downregulated in thyroid carcinoma (TC). Further, Pearson's correlation coefficient revealed a positive correlation between GTF2I expression and FAT1 expression. Therefore, we selected them for this present study, where the effects of bone marrow mesenchymal stem cell-derived EVs (BMSDs-EVs) enriched with GTF2I were evaluated on the epithelial-to-mesenchymal transition (EMT) and stemness maintenance in TC. The under-expression of GTF2I and FAT1 was validated in TC cell lines. Ectopically expressed GTF2I and FAT1 were found to augment malignant phenotypes of TC cells, EMT, and stemness maintenance. Mechanistic studies revealed that GTF2I bound to the promoter region of FAT1 and consequently upregulated its expression. MSC-EVs could shuttle GTF2I into TPC-1 cells, where GTF2I inhibited TC malignant phenotypes, EMT, and stemness maintenance by increasing the expression of FAT1 and facilitating the FAT1-mediated CDK4/FOXM1 downregulation. In vivo experiments confirmed that silencing of GTF2I accelerated tumor growth in nude mice. Taken together, our work suggests that GTF2I transferred by MSC-EVs confer antioncogenic effects through the FAT1/CDK4/FOXM1 axis and may be used as a promising biomarker for TC treatment.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1186-1203"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10236574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. BGB-A445是一种新型的非配体阻断激动性抗OX40抗体,在临床前模型中表现出优异的免疫激活和抗肿瘤作用。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-25 DOI: 10.1007/s11684-023-0996-8
Beibei Jiang, Tong Zhang, Minjuan Deng, Wei Jin, Yuan Hong, Xiaotong Chen, Xin Chen, Jing Wang, Hongjia Hou, Yajuan Gao, Wenfeng Gong, Xing Wang, Haiying Li, Xiaosui Zhou, Yingcai Feng, Bo Zhang, Bin Jiang, Xueping Lu, Lijie Zhang, Yang Li, Weiwei Song, Hanzi Sun, Zuobai Wang, Xiaomin Song, Zhirong Shen, Xuesong Liu, Kang Li, Lai Wang, Ye Liu
{"title":"BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.","authors":"Beibei Jiang, Tong Zhang, Minjuan Deng, Wei Jin, Yuan Hong, Xiaotong Chen, Xin Chen, Jing Wang, Hongjia Hou, Yajuan Gao, Wenfeng Gong, Xing Wang, Haiying Li, Xiaosui Zhou, Yingcai Feng, Bo Zhang, Bin Jiang, Xueping Lu, Lijie Zhang, Yang Li, Weiwei Song, Hanzi Sun, Zuobai Wang, Xiaomin Song, Zhirong Shen, Xuesong Liu, Kang Li, Lai Wang, Ye Liu","doi":"10.1007/s11684-023-0996-8","DOIUrl":"10.1007/s11684-023-0996-8","url":null,"abstract":"<p><p>OX40 is a costimulatory receptor that is expressed primarily on activated CD4<sup>+</sup>, CD8<sup>+</sup>, and regulatory T cells. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. However, most of the agonistic anti-OX40 antibodies in the clinic are OX40L-competitive and show limited efficacy. Here, we discovered that BGB-A445, a non-ligand-competitive agonistic anti-OX40 antibody currently under clinical investigation, induced optimal T cell activation without impairing dendritic cell function. In addition, BGB-A445 dose-dependently and significantly depleted regulatory T cells in vitro and in vivo via antibody-dependent cellular cytotoxicity. In the MC38 syngeneic model established in humanized OX40 knock-in mice, BGB-A445 demonstrated robust and dose-dependent antitumor efficacy, whereas the ligand-competitive anti-OX40 antibody showed antitumor efficacy characterized by a hook effect. Furthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody. Taken together, our findings show that BGB-A445, which does not block OX40-OX40L interaction in contrast to clinical-stage anti-OX40 antibodies, shows superior immune-stimulating effects and antitumor efficacy and thus warrants further clinical investigation.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1170-1185"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges. 改善胰腺癌的预后:从流行病学、基因组变化和治疗挑战中获得启示。
IF 8.1 3区 医学
Frontiers of Medicine Pub Date : 2023-12-01 Epub Date: 2023-12-27 DOI: 10.1007/s11684-023-1050-6
Zhichen Jiang, Xiaohao Zheng, Min Li, Mingyang Liu
{"title":"Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges.","authors":"Zhichen Jiang, Xiaohao Zheng, Min Li, Mingyang Liu","doi":"10.1007/s11684-023-1050-6","DOIUrl":"10.1007/s11684-023-1050-6","url":null,"abstract":"<p><p>Pancreatic cancer, notorious for its late diagnosis and aggressive progression, poses a substantial challenge owing to scarce treatment alternatives. This review endeavors to furnish a holistic insight into pancreatic cancer, encompassing its epidemiology, genomic characterization, risk factors, diagnosis, therapeutic strategies, and treatment resistance mechanisms. We delve into identifying risk factors, including genetic predisposition and environmental exposures, and explore recent research advancements in precursor lesions and molecular subtypes of pancreatic cancer. Additionally, we highlight the development and application of multi-omics approaches in pancreatic cancer research and discuss the latest combinations of pancreatic cancer biomarkers and their efficacy. We also dissect the primary mechanisms underlying treatment resistance in this malignancy, illustrating the latest therapeutic options and advancements in the field. Conclusively, we accentuate the urgent demand for more extensive research to enhance the prognosis for pancreatic cancer patients.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":"1135-1169"},"PeriodicalIF":8.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信